7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Bone Diseases, Metabolic D001851 9 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Obesity D009765 29 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Rubin J et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. 2002 J. Clin. Endocrinol. Metab. pmid:12213884
Palmqvist P et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. 2002 J. Immunol. pmid:12218157
Sandor M et al. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. 2002 Biomaterials pmid:12219832
Shiotani A et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 Anat. Rec. pmid:12221720
Kudo O et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 J. Pathol. pmid:12237882
Hofbauer LC et al. High bone density due to a mutation in LDL-receptor-related protein 5. 2002 N. Engl. J. Med. pmid:12240686
Williamson E et al. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. 2002 J. Immunol. pmid:12244151
Ferrer Cañabate J et al. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]. 2002 An Med Interna pmid:12244784
Kazama JJ et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. 2002 Nephrol. Dial. Transplant. pmid:12271009
Lee SW et al. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. 2002 J. Biochem. Mol. Biol. pmid:12296995
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
pmid:12354528
Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. 2002 Arthritis Rheum. pmid:12355500
Palenzuela L et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. 2002 J. Med. Genet. pmid:12362049
Fu Q et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 J. Biol. Chem. pmid:12364326
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Rude RK et al. Magnesium deficiency: effect on bone and mineral metabolism in the mouse. 2003 Calcif. Tissue Int. pmid:12370796
David JP et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. 2002 J. Cell. Sci. pmid:12376563
Jones DH et al. Role of RANKL and RANK in bone loss and arthritis. 2002 Ann. Rheum. Dis. pmid:12379618
Gravallese EM Bone destruction in arthritis. 2002 Ann. Rheum. Dis. pmid:12379632
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Suda T et al. [Merger of bone biology and immunology]. 2002 Tanpakushitsu Kakusan Koso pmid:12385106
Nagasawa T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. 2002 Clin. Exp. Immunol. pmid:12390325
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Okada Y et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. 2002 Endocr. J. pmid:12402981
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Roodman GD Role of the bone marrow microenvironment in multiple myeloma. 2002 J. Bone Miner. Res. pmid:12412796
Hegedus D et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. 2002 J. Bone Miner. Res. pmid:12412803
Zhao S et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. 2002 J. Bone Miner. Res. pmid:12412815
Hu Y and Yu S Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. 2002 Zhonghua Bing Li Xue Za Zhi pmid:12419159
Sezer O et al. RANK ligand and osteoprotegerin in myeloma bone disease. 2003 Blood pmid:12424190
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Lubberts E et al. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. 2002 Arthritis Rheum. pmid:12428250
Crotti TN et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. 2002 Ann. Rheum. Dis. pmid:12429533
Hofbauer LC and Schoppet M Osteoprotegerin deficiency and juvenile Paget's disease. 2002 N. Engl. J. Med. pmid:12432053
Liegibel UM et al. Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. 2002 J. Exp. Med. pmid:12438430
Bolon B et al. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 Cell. Mol. Life Sci. pmid:12440777
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Shimizu-Ishiura M et al. Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. 2002 J Electron Microsc (Tokyo) pmid:12455916
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Cho CH and Nuttall ME Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. 2002 Expert Opin. Ther. Targets pmid:12472380
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Avbersek-Luznik I et al. Increased levels of osteoprotegerin in hemodialysis patients. 2002 Clin. Chem. Lab. Med. pmid:12476941
Buckley KA et al. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. 2002 Bone pmid:12477572
McCauley LK and Nohutcu RM Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy. 2002 J. Periodontol. pmid:12479643

Table of Content